Amendments to the Claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-121 (Cancelled).

122 (Currently Amended). A pharmaceutical composition in unit dosage form ~~for treating Alzheimer's disease~~, comprising a pharmaceutically acceptable carrier, and, as an active ingredient, ~~an effective amount of~~ a virus that is an *in vivo* non-propagatable particle displaying a polypeptide, wherein said polypeptide comprises at least one epitope of beta-amyloid (Aβ), and wherein said at least one epitope ~~is capable of eliciting~~elicits Aβ-binding antibodies against said epitope when administered to a subject, and wherein said ~~which an effective amount of~~ antibodies ~~is capable of~~ inhibit~~ing~~ aggregation of said beta-amyloid~~, and a pharmaceutically acceptable carrier~~.

123 (Cancelled).

124 (Previously Presented). The pharmaceutical composition of claim 122, wherein said virus is selected from the group consisting of a double stranded DNA virus, a single stranded DNA virus, a positive strand RNA virus and a negative strand RNA virus.

125 (Previously Presented). The pharmaceutical composition of claim 122, wherein said virus is a bacteriophage.

126 (Previously Presented). The pharmaceutical composition of claim 125, wherein said bacteriophage is capable of propagation in bacterial flora in said recipient.

127 (Previously Presented). The pharmaceutical composition of claim 125, wherein said bacteriophage is capable of propagation in Escherichia coli.

128 (Previously Presented). The pharmaceutical composition of claim 122, wherein the Alzheimer's disease is early onset Alzheimer's disease.

129 (Previously Presented). The pharmaceutical composition of claim 122, wherein the Alzheimer's disease is late onset Alzheimer's disease.

130 (Previously Presented). The pharmaceutical composition of claim 122, wherein the Alzheimer's disease is presymptomatic Alzheimer's disease.

131 (Previously Presented). The pharmaceutical composition of claim 122, wherein said virus is selected such that less than 30 days following an introduction of a triple dose of 10^{10} units thereof to the recipient, a titer of said antibodies is above 1:50,000, as is determined by ELISA.

132 (Withdrawn). A method of treating Alzheimer's disease, comprising introducing a pharmaceutical composition in accordance with claim 122 into a body of a recipient in need thereof so as to inhibit aggregation of beta-amyloid and treat Alzheimer's disease.

133 (Cancelled).

134 (Withdrawn). The method of claim 132, wherein said virus is selected from the group consisting of a double stranded DNA virus, a single stranded DNA virus, a positive strand RNA virus and a negative strand RNA virus.

135 (Previously Presented). The method of claim 132, wherein said virus is a bacteriophage.

136 (Previously Presented). The method of claim 135, wherein said bacteriophage is capable of propagation in bacterial flora in said recipient.

137 (Previously Presented). The method of claim 135, wherein said bacteriophage is capable of propagation in Escherichia coli.

138 (Withdrawn). The method of claim 132, wherein the Alzheimer's disease is early onset Alzheimer's disease.

139 (Withdrawn). The method of claim 132, wherein the Alzheimer's disease is late onset Alzheimer's disease.

140 (Withdrawn). The method of claim 132, wherein the Alzheimer's disease is presymptomatic Alzheimer's disease.

141 (Withdrawn - Currently Amended). The method of claim 132, wherein ~~introducing~~ said virus is introduced into the body of the recipient so as to inhibit aggregation of beta-amyloid ~~is~~ by applying said virus to an olfactory system of the recipient.

142 (New). A composition in accordance with claim 122, wherein said polypeptide is Aβ.

143 (New). A composition in accordance with claim 122, wherein said epitope is EFRH (SEQ ID NO:1), DAEFRH

(residues 1-6 of SEQ ID NO:3), DAEFRHD (residues 1-7 of SEQ ID NO:3), or DAEFRHDSG (residues 1-9 of SEQ ID NO:3).

144 (New). A composition in accordance with claim 122, wherein said epitope comprises EFRH (SEQ ID NO:1).

145 (New). A method in accordance with claim 132, wherein said polypeptide is Aβ.

146 (New). A method in accordance with claim 132, wherein said epitope is EFRH (SEQ ID NO:1), DAEFRH (residues 1-6 of SEQ ID NO:3), DAEFRHD (residues 1-7 of SEQ ID NO:3), or DAEFRHDSG (residues 1-9 of SEQ ID NO:3).

147 (New). A method in accordance with claim 132, wherein said epitope comprises EFRH (SEQ ID NO:1).